FDA Adds a Vision-Loss Warning to Every GLP-1 Drug Label
The agency cites a higher rate of a rare optic nerve condition, NAION, in trials and studies, though it says cause and effect has not been established.

The Food and Drug Administration said Monday, November 9, that it is requiring the makers of all GLP-1 medications, including Wegovy, Ozempic, Mounjaro and Zepbound, to add a warning about a potential increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION, CNBC reports. The rare condition is caused by reduced blood flow to the front of the optic nerve and can cause sudden loss of vision, sometimes permanently.
NAION cases have been reported with every GLP-1 product on the market, the FDA said. An analysis of 126 trials with more than 134,000 patients found 6.4 cases per 100,000 patient-years among people taking GLP-1 drugs, compared with 3.8 among those on other treatments or placebo, and several observational studies also found an increased risk. The agency says the condition is rare and that a causal relationship has not been established.
Novo Nordisk, which makes Ozempic and Wegovy, said it "continues to believe the data do not establish a cause-and-effect relationship" and remains confident in the drugs' benefit-risk profile. CNBC said it had asked Eli Lilly, maker of Mounjaro and Zepbound, for comment.
Sources